Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study - Abou-Alfa, GK; Macarulla, T; Javle, MM (Lancet Oncol, 2020)
et al.